 | • レポートコード：MRC23Q36577 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の抗感染症薬市場について調査・分析し、世界の抗感染症薬市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（抗菌薬、抗真菌薬、抗ウイルス薬、抗寄生虫薬）、用途別セグメント分析（病院、医学研究所、診療所、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Aridis Pharmaceuticals、AiCuris、Sandoz、Anhui Jingfang Medical Industry Co.,Ltd、Beijing Double-Crane Pharmaceutical Co., Ltd.、Abbott、Spero Therapeutics、Adlyfe, Inc.、Advanced Life Sciences Holdings, Inc.、Affinium Pharmaceuticals、APP Pharmaceuticals、Aquapharm Biodiscovery、Basilea Pharmaceutica AG、Biophage Pharma, Inc.などが含まれています。 世界の抗感染症薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、抗感染症薬市場規模を推定する際に考慮しました。本レポートは、抗感染症薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、抗感染症薬に関するビジネス上の意思決定に役立てることを目的としています。 ・抗感染症薬市場の概要 - 製品の定義 - 抗感染症薬のタイプ別セグメント - 世界の抗感染症薬市場規模：タイプ別分析（抗菌薬、抗真菌薬、抗ウイルス薬、抗寄生虫薬） - 抗感染症薬の用途別セグメント - 世界の抗感染症薬市場規模：用途別分析（病院、医学研究所、診療所、その他） - 世界の抗感染症薬市場規模予測（2018年-2029年） - 抗感染症薬の平均価格推移（2018年-2029年） - 前提条件と制限事項 ・メーカー別競争状況 - メーカー別市場シェア - 世界の主要メーカー、業界ランキング分析 - メーカー別平均価格 - 抗感染症薬市場の競争状況およびトレンド ・抗感染症薬の地域別市場規模 - 北米の抗感染症薬市場規模（2018年-2029年） - アメリカの抗感染症薬市場規模（2018年-2029年） - ヨーロッパの抗感染症薬市場規模（2018年-2029年） - アジア太平洋の抗感染症薬市場規模（2018年-2029年） - 中国の抗感染症薬市場規模（2018年-2029年） - 日本の抗感染症薬市場規模（2018年-2029年） - 韓国の抗感染症薬市場規模（2018年-2029年） - インドの抗感染症薬市場規模（2018年-2029年） - オーストラリアの抗感染症薬市場規模（2018年-2029年） - 中南米の抗感染症薬市場規模（2018年-2029年） - 中東・アフリカの抗感染症薬市場規模（2018年-2029年） ・タイプ別セグメント：抗菌薬、抗真菌薬、抗ウイルス薬、抗寄生虫薬 - 世界の抗感染症薬のタイプ別販売量（2018年-2023年） - 世界の抗感染症薬のタイプ別売上（2018年-2023年） - 世界の抗感染症薬のタイプ別価格 ・用途別セグメント：病院、医学研究所、診療所、その他 - 世界の抗感染症薬の用途別販売量（2018年-2023年） - 世界の抗感染症薬の用途別売上（2018年-2023年） - 世界の抗感染症薬の用途別価格 ・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向 Aridis Pharmaceuticals、AiCuris、Sandoz、Anhui Jingfang Medical Industry Co.,Ltd、Beijing Double-Crane Pharmaceutical Co., Ltd.、Abbott、Spero Therapeutics、Adlyfe, Inc.、Advanced Life Sciences Holdings, Inc.、Affinium Pharmaceuticals、APP Pharmaceuticals、Aquapharm Biodiscovery、Basilea Pharmaceutica AG、Biophage Pharma, Inc. ・産業チェーンと販売チャネルの分析 - 抗感染症薬産業チェーン分析 - 抗感染症薬の主要原材料 - 抗感染症薬の販売チャネル - 抗感染症薬のディストリビューター - 抗感染症薬の主要顧客 ・抗感染症薬市場ダイナミクス - 抗感染症薬の業界動向 - 抗感染症薬市場の成長ドライバ、課題、阻害要因 ・調査成果および結論 ・調査方法とデータソース |
Highlights
The global Anti-infectious Disease Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Anti-infectious Disease Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Anti-infectious Disease Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Anti-infectious Disease Drugs include Aridis Pharmaceuticals, AiCuris, Sandoz, Anhui Jingfang Medical Industry Co.,Ltd, Beijing Double-Crane Pharmaceutical Co., Ltd., Abbott, Spero Therapeutics, Adlyfe, Inc. and Advanced Life Sciences Holdings, Inc., etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Anti-infectious Disease Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-infectious Disease Drugs.
The Anti-infectious Disease Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Anti-infectious Disease Drugs market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-infectious Disease Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Aridis Pharmaceuticals
AiCuris
Sandoz
Anhui Jingfang Medical Industry Co.,Ltd
Beijing Double-Crane Pharmaceutical Co., Ltd.
Abbott
Spero Therapeutics
Adlyfe, Inc.
Advanced Life Sciences Holdings, Inc.
Affinium Pharmaceuticals
APP Pharmaceuticals
Aquapharm Biodiscovery
Basilea Pharmaceutica AG
Biophage Pharma, Inc.
Segment by Type
Antibacterial Drugs
Antifungal Drugs
Antiviral Drugs
Antiparasitic Drugs
Segment by Application
Hospital
Institute of Medicine
Clinic
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-infectious Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-infectious Disease Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Anti-infectious Disease Drugs Market Overview
1.1 Product Overview and Scope of Anti-infectious Disease Drugs
1.2 Anti-infectious Disease Drugs Segment by Type
1.2.1 Global Anti-infectious Disease Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Antibacterial Drugs
1.2.3 Antifungal Drugs
1.2.4 Antiviral Drugs
1.2.5 Antiparasitic Drugs
1.3 Anti-infectious Disease Drugs Segment by Application
1.3.1 Global Anti-infectious Disease Drugs Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Institute of Medicine
1.3.4 Clinic
1.3.5 Others
1.4 Global Anti-infectious Disease Drugs Market Size Estimates and Forecasts
1.4.1 Global Anti-infectious Disease Drugs Revenue 2018-2029
1.4.2 Global Anti-infectious Disease Drugs Sales 2018-2029
1.4.3 Global Anti-infectious Disease Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Anti-infectious Disease Drugs Market Competition by Manufacturers
2.1 Global Anti-infectious Disease Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Anti-infectious Disease Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Anti-infectious Disease Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Anti-infectious Disease Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Anti-infectious Disease Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-infectious Disease Drugs, Product Type & Application
2.7 Anti-infectious Disease Drugs Market Competitive Situation and Trends
2.7.1 Anti-infectious Disease Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Anti-infectious Disease Drugs Players Market Share by Revenue
2.7.3 Global Anti-infectious Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-infectious Disease Drugs Retrospective Market Scenario by Region
3.1 Global Anti-infectious Disease Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Anti-infectious Disease Drugs Global Anti-infectious Disease Drugs Sales by Region: 2018-2029
3.2.1 Global Anti-infectious Disease Drugs Sales by Region: 2018-2023
3.2.2 Global Anti-infectious Disease Drugs Sales by Region: 2024-2029
3.3 Global Anti-infectious Disease Drugs Global Anti-infectious Disease Drugs Revenue by Region: 2018-2029
3.3.1 Global Anti-infectious Disease Drugs Revenue by Region: 2018-2023
3.3.2 Global Anti-infectious Disease Drugs Revenue by Region: 2024-2029
3.4 North America Anti-infectious Disease Drugs Market Facts & Figures by Country
3.4.1 North America Anti-infectious Disease Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Anti-infectious Disease Drugs Sales by Country (2018-2029)
3.4.3 North America Anti-infectious Disease Drugs Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Anti-infectious Disease Drugs Market Facts & Figures by Country
3.5.1 Europe Anti-infectious Disease Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Anti-infectious Disease Drugs Sales by Country (2018-2029)
3.5.3 Europe Anti-infectious Disease Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-infectious Disease Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Anti-infectious Disease Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Anti-infectious Disease Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Anti-infectious Disease Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Anti-infectious Disease Drugs Market Facts & Figures by Country
3.7.1 Latin America Anti-infectious Disease Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Anti-infectious Disease Drugs Sales by Country (2018-2029)
3.7.3 Latin America Anti-infectious Disease Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Anti-infectious Disease Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-infectious Disease Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Anti-infectious Disease Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Anti-infectious Disease Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-infectious Disease Drugs Sales by Type (2018-2029)
4.1.1 Global Anti-infectious Disease Drugs Sales by Type (2018-2023)
4.1.2 Global Anti-infectious Disease Drugs Sales by Type (2024-2029)
4.1.3 Global Anti-infectious Disease Drugs Sales Market Share by Type (2018-2029)
4.2 Global Anti-infectious Disease Drugs Revenue by Type (2018-2029)
4.2.1 Global Anti-infectious Disease Drugs Revenue by Type (2018-2023)
4.2.2 Global Anti-infectious Disease Drugs Revenue by Type (2024-2029)
4.2.3 Global Anti-infectious Disease Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Anti-infectious Disease Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Anti-infectious Disease Drugs Sales by Application (2018-2029)
5.1.1 Global Anti-infectious Disease Drugs Sales by Application (2018-2023)
5.1.2 Global Anti-infectious Disease Drugs Sales by Application (2024-2029)
5.1.3 Global Anti-infectious Disease Drugs Sales Market Share by Application (2018-2029)
5.2 Global Anti-infectious Disease Drugs Revenue by Application (2018-2029)
5.2.1 Global Anti-infectious Disease Drugs Revenue by Application (2018-2023)
5.2.2 Global Anti-infectious Disease Drugs Revenue by Application (2024-2029)
5.2.3 Global Anti-infectious Disease Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Anti-infectious Disease Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Aridis Pharmaceuticals
6.1.1 Aridis Pharmaceuticals Corporation Information
6.1.2 Aridis Pharmaceuticals Description and Business Overview
6.1.3 Aridis Pharmaceuticals Anti-infectious Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Aridis Pharmaceuticals Anti-infectious Disease Drugs Product Portfolio
6.1.5 Aridis Pharmaceuticals Recent Developments/Updates
6.2 AiCuris
6.2.1 AiCuris Corporation Information
6.2.2 AiCuris Description and Business Overview
6.2.3 AiCuris Anti-infectious Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 AiCuris Anti-infectious Disease Drugs Product Portfolio
6.2.5 AiCuris Recent Developments/Updates
6.3 Sandoz
6.3.1 Sandoz Corporation Information
6.3.2 Sandoz Description and Business Overview
6.3.3 Sandoz Anti-infectious Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Sandoz Anti-infectious Disease Drugs Product Portfolio
6.3.5 Sandoz Recent Developments/Updates
6.4 Anhui Jingfang Medical Industry Co.,Ltd
6.4.1 Anhui Jingfang Medical Industry Co.,Ltd Corporation Information
6.4.2 Anhui Jingfang Medical Industry Co.,Ltd Description and Business Overview
6.4.3 Anhui Jingfang Medical Industry Co.,Ltd Anti-infectious Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Anhui Jingfang Medical Industry Co.,Ltd Anti-infectious Disease Drugs Product Portfolio
6.4.5 Anhui Jingfang Medical Industry Co.,Ltd Recent Developments/Updates
6.5 Beijing Double-Crane Pharmaceutical Co., Ltd.
6.5.1 Beijing Double-Crane Pharmaceutical Co., Ltd. Corporation Information
6.5.2 Beijing Double-Crane Pharmaceutical Co., Ltd. Description and Business Overview
6.5.3 Beijing Double-Crane Pharmaceutical Co., Ltd. Anti-infectious Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Beijing Double-Crane Pharmaceutical Co., Ltd. Anti-infectious Disease Drugs Product Portfolio
6.5.5 Beijing Double-Crane Pharmaceutical Co., Ltd. Recent Developments/Updates
6.6 Abbott
6.6.1 Abbott Corporation Information
6.6.2 Abbott Description and Business Overview
6.6.3 Abbott Anti-infectious Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Abbott Anti-infectious Disease Drugs Product Portfolio
6.6.5 Abbott Recent Developments/Updates
6.7 Spero Therapeutics
6.6.1 Spero Therapeutics Corporation Information
6.6.2 Spero Therapeutics Description and Business Overview
6.6.3 Spero Therapeutics Anti-infectious Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Spero Therapeutics Anti-infectious Disease Drugs Product Portfolio
6.7.5 Spero Therapeutics Recent Developments/Updates
6.8 Adlyfe, Inc.
6.8.1 Adlyfe, Inc. Corporation Information
6.8.2 Adlyfe, Inc. Description and Business Overview
6.8.3 Adlyfe, Inc. Anti-infectious Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Adlyfe, Inc. Anti-infectious Disease Drugs Product Portfolio
6.8.5 Adlyfe, Inc. Recent Developments/Updates
6.9 Advanced Life Sciences Holdings, Inc.
6.9.1 Advanced Life Sciences Holdings, Inc. Corporation Information
6.9.2 Advanced Life Sciences Holdings, Inc. Description and Business Overview
6.9.3 Advanced Life Sciences Holdings, Inc. Anti-infectious Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Advanced Life Sciences Holdings, Inc. Anti-infectious Disease Drugs Product Portfolio
6.9.5 Advanced Life Sciences Holdings, Inc. Recent Developments/Updates
6.10 Affinium Pharmaceuticals
6.10.1 Affinium Pharmaceuticals Corporation Information
6.10.2 Affinium Pharmaceuticals Description and Business Overview
6.10.3 Affinium Pharmaceuticals Anti-infectious Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Affinium Pharmaceuticals Anti-infectious Disease Drugs Product Portfolio
6.10.5 Affinium Pharmaceuticals Recent Developments/Updates
6.11 APP Pharmaceuticals
6.11.1 APP Pharmaceuticals Corporation Information
6.11.2 APP Pharmaceuticals Anti-infectious Disease Drugs Description and Business Overview
6.11.3 APP Pharmaceuticals Anti-infectious Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 APP Pharmaceuticals Anti-infectious Disease Drugs Product Portfolio
6.11.5 APP Pharmaceuticals Recent Developments/Updates
6.12 Aquapharm Biodiscovery
6.12.1 Aquapharm Biodiscovery Corporation Information
6.12.2 Aquapharm Biodiscovery Anti-infectious Disease Drugs Description and Business Overview
6.12.3 Aquapharm Biodiscovery Anti-infectious Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Aquapharm Biodiscovery Anti-infectious Disease Drugs Product Portfolio
6.12.5 Aquapharm Biodiscovery Recent Developments/Updates
6.13 Basilea Pharmaceutica AG
6.13.1 Basilea Pharmaceutica AG Corporation Information
6.13.2 Basilea Pharmaceutica AG Anti-infectious Disease Drugs Description and Business Overview
6.13.3 Basilea Pharmaceutica AG Anti-infectious Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Basilea Pharmaceutica AG Anti-infectious Disease Drugs Product Portfolio
6.13.5 Basilea Pharmaceutica AG Recent Developments/Updates
6.14 Biophage Pharma, Inc.
6.14.1 Biophage Pharma, Inc. Corporation Information
6.14.2 Biophage Pharma, Inc. Anti-infectious Disease Drugs Description and Business Overview
6.14.3 Biophage Pharma, Inc. Anti-infectious Disease Drugs Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Biophage Pharma, Inc. Anti-infectious Disease Drugs Product Portfolio
6.14.5 Biophage Pharma, Inc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-infectious Disease Drugs Industry Chain Analysis
7.2 Anti-infectious Disease Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-infectious Disease Drugs Production Mode & Process
7.4 Anti-infectious Disease Drugs Sales and Marketing
7.4.1 Anti-infectious Disease Drugs Sales Channels
7.4.2 Anti-infectious Disease Drugs Distributors
7.5 Anti-infectious Disease Drugs Customers
8 Anti-infectious Disease Drugs Market Dynamics
8.1 Anti-infectious Disease Drugs Industry Trends
8.2 Anti-infectious Disease Drugs Market Drivers
8.3 Anti-infectious Disease Drugs Market Challenges
8.4 Anti-infectious Disease Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer